Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Nash

Showing results (1-10 of 198) with videos related to

Pageof 20
Sort By:
The Journal of Rheumatology|January 2, 2021
Real-world Evidence Needs Careful InterpretationPeter Nash
Rheumatology (Oxford, England)|May 5, 2021
Clinical use of Jak 1 inhibitors for rheumatoid arthritisPeter Nash
Nature Reviews. Rheumatology|December 19, 2022
JAK inhibitors: new indication and emerging safety data in 2022Peter Nash
Annals of the Rheumatic Diseases|February 9, 2020
2019 update: EULAR RA management recommendations, efficacy and safety systematic literature reviewsPeter Nash
The Journal of Rheumatology|August 3, 2020
How Can We Improve the Use of Established Therapies in PsA?Peter Nash
Lancet (London, England)|June 13, 2018
Psoriatic arthritis: novel targets add to a therapeutic renaissancePeter Nash
The Journal of Rheumatology|May 26, 2006
Therapies for axial disease in psoriatic arthritis. A systematic reviewPeter Nash
Joint Bone Spine|August 6, 2022
Telemedicine and rheumatologyPeter Nash
Current Rheumatology Reports|August 21, 2009
Assessment and treatment of psoriatic spondylitisPeter Nash
Nature Clinical Practice. Rheumatology|September 5, 2006
Alefacept plus methotrexate for psoriatic arthritisPeter Nash
Pageof 20

Showing results (1-10 of 198) with videos related to

Sort By:
Pageof 20
The Journal of Rheumatology|January 2, 2021
Real-world Evidence Needs Careful InterpretationPeter Nash
Rheumatology (Oxford, England)|May 5, 2021
Clinical use of Jak 1 inhibitors for rheumatoid arthritisPeter Nash
Nature Reviews. Rheumatology|December 19, 2022
JAK inhibitors: new indication and emerging safety data in 2022Peter Nash
Annals of the Rheumatic Diseases|February 9, 2020
2019 update: EULAR RA management recommendations, efficacy and safety systematic literature reviewsPeter Nash
The Journal of Rheumatology|August 3, 2020
How Can We Improve the Use of Established Therapies in PsA?Peter Nash
Lancet (London, England)|June 13, 2018
Psoriatic arthritis: novel targets add to a therapeutic renaissancePeter Nash
The Journal of Rheumatology|May 26, 2006
Therapies for axial disease in psoriatic arthritis. A systematic reviewPeter Nash
Joint Bone Spine|August 6, 2022
Telemedicine and rheumatologyPeter Nash
Current Rheumatology Reports|August 21, 2009
Assessment and treatment of psoriatic spondylitisPeter Nash
Nature Clinical Practice. Rheumatology|September 5, 2006
Alefacept plus methotrexate for psoriatic arthritisPeter Nash
Pageof 20